The phase III trial COURAGE-ALS of investigational reldesemtiv, a fast skeletal troponin activator, did not meet its primary ...

The invasive nature of lipid biopsies has lead researchers to dedicate more efforts to unveiling noninvasive diagnostic methods for metabolic dysfunction–associated steatohepatitis (MASH).

The one-time therapy appears to correct the mutation that causes the disease, known as Alpha-1 antitrypsin deficiency (AATD), with a higher dose leading to more functional molecules of the protein ...

Cruciferous vegetables such as broccoli, cauliflower, and Brussels sprouts could benefit those with fatty liver disease.

NAFLD, the most prevalent liver disease, affects approximately 25% of the global population (1.2 billion people), including 188 million in India. Left untreated, NAFLD can progress to non-alcoholic ...

The liver is a vital organ responsible for detoxifying toxins. Certain foods can 'clean out your liver' and reduce your risk of fatty liver disease.

Beam Therapeutics (BEAM) announced initial safety and efficacy data from its Phase 1/2 trial of BEAM-302, establishing clinical ...

Top-Line Data From MAD Part 2 of the Phase 1 Trial of DA-1726 Expected in April of 2025 Announced Positive Top-Line 16-Week Results from the Phase 2a Trial of DA-1241 ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...

The number one unmet need is that we don't have a good handle on who's at risk, because patients generally don't have too many ...